UNIMED announced that its Board, which met on April 27, 2023, examined the company’s activity report and approved the financial statements for the year ended 31 December 2022.
It appears that the 2022 financial year was marked by an increase in turnover and the gradual resumption of sales to the Central Pharmacy of Tunisia (PCT).
In fact, UNIMED achieved a net profit of 7.8 million dinars in 2022, compared with 8.7 million the previous year.
As for the turnover, it amounts to 96.3 million dinars, broken down as follows 43% for domestic sales, i.e. 41.6 million dinars, and 57% for export sales, i.e. 54.7 million dinars.
The Board has therefore decided to propose to the Annual General Meeting to be held on June 2 the distribution of a dividend of 15 million dinars, i.e. 0.468 dinars per share to be deducted from the retained earnings, compared to 0.410 dinars last year.
The Board o also proposes that these dividends be paid no later than July 31, 2023.
